Avalo Reports Second Quarter 2025 Financial Results and
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead
Avalo Therapeutics Announces Inducement Grants to New
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead
Avalo Completes Divestiture of AVTX-800 Series
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling
Avalo Therapeutics, Inc. (AVTX)
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo''s lead asset is AVTX-009, an anti-IL-1β mAb,
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo''s lead asset is AVTX-009, an anti-IL-1β mAb,
Pipeline
Progressing product candidates targeting immune-mediated inflammatory diseases We are advancing a pipeline that emphasizes a high-value, potentially best-in-class and best-in
Press Releases :: Avalo Therapeutics, Inc. (AVTX)
Oct 29, 2025 7:00 am EDT Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa